Experimental vaccine developed by scientists shows promising results against Epstein-Barr virus

do you know Epstein-Barr virus (EBV) is the most common cause infectious monocytes? It is a type of human herpesvirus 4 and is usually transmitted in adolescents and young adults because it is transmitted through bodily fluids, especially saliva.

Given its ease of dissemination, the QIMR Berghofer Institute for Medical Research has developed a new experimental vaccine that has achieved effective and long-lasting immune protection in mice.

dosage for lymph nodescritical part in operation the body’s immune system.According to its authors, the vaccine not only produced powerful antibodies and T cells to fight the virus Webbbut has also been shown to induce a specific type of immunity to prevent virus-associated tumor growth.

“What we’ve done is we’ve engineered what we call the other arm of the immune system, which we call T cells, and we’ve combined that with an antibody, and this new formulation will induce an antibody and T cell immune response,” he said in a statement. One paper explained that Rajiv Khanna was an immunologist.

How does it work?this Antibodies bind unwanted invading pathogens delete them while T cells directly destroys these pathogens and helps coordinate physical defense.

The researchers are nearing the final stages of its creation. If EBV goes untreated, it can lead to cancers of the throat and nose, as well as multiple sclerosis.

The study was published in nature.